JP2017523959A - ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 - Google Patents

ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 Download PDF

Info

Publication number
JP2017523959A
JP2017523959A JP2016575360A JP2016575360A JP2017523959A JP 2017523959 A JP2017523959 A JP 2017523959A JP 2016575360 A JP2016575360 A JP 2016575360A JP 2016575360 A JP2016575360 A JP 2016575360A JP 2017523959 A JP2017523959 A JP 2017523959A
Authority
JP
Japan
Prior art keywords
absent
lys
ala
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016575360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523959A5 (enExample
Inventor
グレゴリー トーマス ボーン，
グレゴリー トーマス ボーン，
マーク レスリー スマイス，
マーク レスリー スマイス，
ブライアン トロイ フレデリック，
ブライアン トロイ フレデリック，
シモネ ビンク，
シモネ ビンク，
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド, プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2017523959A publication Critical patent/JP2017523959A/ja
Publication of JP2017523959A5 publication Critical patent/JP2017523959A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016575360A 2014-06-27 2015-06-29 ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 Withdrawn JP2017523959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018382P 2014-06-27 2014-06-27
US62/018,382 2014-06-27
PCT/US2015/038370 WO2015200916A2 (en) 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof

Publications (2)

Publication Number Publication Date
JP2017523959A true JP2017523959A (ja) 2017-08-24
JP2017523959A5 JP2017523959A5 (enExample) 2019-02-28

Family

ID=54938965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575360A Withdrawn JP2017523959A (ja) 2014-06-27 2015-06-29 ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用

Country Status (10)

Country Link
US (2) US20170313754A1 (enExample)
EP (1) EP3161164A4 (enExample)
JP (1) JP2017523959A (enExample)
KR (1) KR20170043509A (enExample)
CN (1) CN107075574A (enExample)
AU (1) AU2015279571A1 (enExample)
CA (1) CA2953721A1 (enExample)
IL (1) IL249692A0 (enExample)
SG (1) SG11201610799WA (enExample)
WO (1) WO2015200916A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532728A (ja) * 2020-07-02 2023-07-31 タンペレ・ユニバーシティー・ファウンデーション・エスアール レニンに基づくヘプシジン分析法
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448382C (en) 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
WO2019018377A1 (en) * 2017-07-18 2019-01-24 Arizona Board Of Regents On Behalf Of The University Of Arizona DISULFIDE-MASKED PRO-CHELATE COMPOSITIONS AND METHODS OF USE
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
KR20180109917A (ko) * 2016-01-08 2018-10-08 라 졸라 파마슈티칼 컴파니 헵시딘의 투여 방법
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
US20180099023A1 (en) * 2016-09-06 2018-04-12 La Jolla Pharmaceutical Company Methods of treating iron overload
JP2020502169A (ja) * 2016-12-19 2020-01-23 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジンを投与する方法
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) * 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3894416B1 (en) 2018-12-13 2022-11-09 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
SG11202111587VA (en) 2019-05-07 2021-11-29 Bayer Ag Masp inhibitory compounds and uses thereof
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
BR112022003999A2 (pt) 2019-09-03 2022-05-31 Protagonist Therapeutics Inc Miméticos de hepcidina conjugados
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
KR20220088699A (ko) * 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
CA3181577A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
MX2022013518A (es) 2020-04-28 2023-02-01 Global Blood Therapeutics Inc Pirimidinas cicloalquiladas como inhibidores de la ferroportina.
CA3181583A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN111560051B (zh) * 2020-05-26 2022-11-25 大连工业大学 一种具有促铁吸收活性的虾源九肽及其应用
CN114252627A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液铁调素及其多肽片段在过敏性疾病中的应用
IL302996B2 (en) 2020-11-20 2025-04-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
CA3213688A1 (en) * 2021-04-01 2022-10-06 Ashok Bhandari Conjugated hepcidin mimetics
KR20240021833A (ko) * 2021-06-14 2024-02-19 프로타고니스트 테라퓨틱스, 인코포레이티드 유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN115703826B (zh) * 2021-08-03 2025-05-06 浙江大学 铁调素改造体及其应用
EP4587034A1 (en) * 2022-09-15 2025-07-23 Migal Galilee Research Institute Ltd Site-specific activation of regulatory t cells
WO2025224128A1 (en) 2024-04-24 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090722A1 (es) * 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
CN101358201A (zh) * 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
WO2011149942A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
CA2855122A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
PT2968443T (pt) * 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532728A (ja) * 2020-07-02 2023-07-31 タンペレ・ユニバーシティー・ファウンデーション・エスアール レニンに基づくヘプシジン分析法
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体

Also Published As

Publication number Publication date
WO2015200916A2 (en) 2015-12-30
AU2015279571A1 (en) 2017-02-02
SG11201610799WA (en) 2017-01-27
EP3161164A2 (en) 2017-05-03
EP3161164A4 (en) 2018-04-25
IL249692A0 (en) 2017-02-28
US20200017566A1 (en) 2020-01-16
CN107075574A (zh) 2017-08-18
CA2953721A1 (en) 2015-12-30
US20170313754A1 (en) 2017-11-02
KR20170043509A (ko) 2017-04-21

Similar Documents

Publication Publication Date Title
US12269856B2 (en) Hepcidin analogues and uses thereof
US20200017566A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
US11753443B2 (en) Conjugated hepcidin mimetics
JP2023540679A (ja) コンジュゲートされたヘプシジン模倣物
WO2022212698A1 (en) Conjugated hepcidin mimetics
JP2024513391A (ja) コンジュゲートされたヘプシジン模倣物
WO2025226506A1 (en) Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm
CN116457000A (zh) 缀合的铁调素模拟物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190328